Facility significantly increases future financial and operational flexibilityUp to $200M available, with $30 million drawn at close and additional $80 million available at Disc’s sole discretion through second-half 2026Funding can support development across the portfolio, including the recently announced potential accelerated approval pathway for bitopertin in EPP WATERTOWN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the ...

WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive additional data from an ongoing Phase 1b study of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia, including results from the 40 mg and 60 mg single ascending dose (SAD) co ...

Core Insights - Disc Medicine, Inc. is set to present clinical data on DISC-0974 at the 2024 ASN Kidney Week, focusing on its Phase 1b study in patients with non-dialysis dependent chronic kidney disease and anemia [1][2] - The study aims to evaluate safety and changes in hepcidin, iron levels, and hematologic parameters [1][2] Presentation Details - The presentation will include data from the 40mg and 60mg dose cohorts, covering safety, pharmacokinetics, and effects on hepcidin and anemia [2][3] - The abstract for the presentation is available on the ASN Kidney Week conference website [2] Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for serious hematologic diseases, focusing on red blood cell biology and iron homeostasis [4]

Core Insights - Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases [3] - The company will participate in four upcoming investor conferences in September 2024 [1] Conference Participation - The company will present at the 2024 Wells Fargo Securities Healthcare Conference on September 6th at 10:15 a.m. ET [1] - The Morgan Stanley 22nd Annual Global Healthcare Conference will also feature the company on September 6th at 1:05 p.m. ET [1] - The H.C. Wainwright 26th Annual Global Investment Conference is scheduled for September 11th at 9:30 a.m. ET [1] - The 2024 Cantor Global Healthcare Conference will take place on September 19th at 8:00 a.m. ET [1] Webcast Information - A live webcast of the fireside chats will be available on the company's investor relations website, with an archived replay accessible after the events [2]

Company Overview - MoneyThumb is a leader in automated document evaluation and fraud detection solutions, founded in 2014, and specializes in underwriting automation software that enhances workflows for funders, lenders, and accountants by converting and analyzing PDF financial documents in seconds [3][6] - The company has developed an AI file tampering detection tool that identifies fraudulent activity quickly, providing lenders with a robust defense against risk and loan losses [3][6] Acquisition Details - MoneyThumb has been acquired by Iron Creek Partners LLC, a private investment firm focused on software, data, communications, and business services industries, with the transaction closing on August 19, 2024 [1][4] - The acquisition is expected to provide growth capital to meet MoneyThumb's strong industry demand, which has resulted in 100% year-over-year growth [1][4] Leadership Changes - Ryan Campbell, who has been with MoneyThumb since 2017, has been appointed as the new CEO and will join the investor group, while founder Ralph Mayer will transition to an advisory role and retain his board seat [2] Strategic Goals - The acquisition is seen as a milestone for MoneyThumb, with plans to accelerate growth and continue delivering exceptional software solutions to help lenders manage risk and provide capital to small businesses more efficiently [4] - Iron Creek Partners aims to leverage its sector experience and relationships to support MoneyThumb's growth and broaden its product suite [4][7]

The securities described above are being offered by Disc pursuant to a shelf registration statement on Form S-3 (No. 333-275652) that was declared effective by the Securities and Exchange Commission (SEC) on November 29, 2023. This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website at www. ...

Company Overview - Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases [9]. Recent Offering - Disc announced the pricing of an underwritten offering of 4,944,000 shares of its common stock at a price of $36.00 per share, with expected gross proceeds of approximately $178.0 million before deductions [3]. - The offering is expected to close on June 17, 2024, subject to customary closing conditions [3]. Use of Proceeds - The net proceeds from the offering will be used to fund research and clinical development of current or additional product candidates, as well as for working capital and other general corporate purposes [2]. Financing Details - The financing was led by Frazier Life Sciences and Logos Capital, with participation from various institutional investors including Access Biotechnology and Wellington Management [7]. Regulatory Information - The securities are being offered pursuant to a shelf registration statement on Form S-3, which was declared effective by the SEC on November 29, 2023 [8].

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive additional data for bitopertin in erythropoietic protoporphyria (EPP), including additional analyses of AURORA data that further demonstrated the clinical activity of bitopertin and highlighted meaningful improvements ...

Core Insights - Disc Medicine, Inc. is set to present data from its hematology portfolio at the European Hematology Association (EHA) 2024 Congress in Madrid from June 13-16, 2024 [1][2] - The company will showcase four posters highlighting the therapeutic potential of three clinical-stage drugs [2] - Management will conduct a call on June 14, 2024, to review the presented data [2] Presentation Details - Abstract P1575 will present topline results from the AURORA Trial, a Phase 2, randomized, double-blind, placebo-controlled trial of Bitopertin in Erythropoietic Protoporphyria, scheduled for June 14 at 6:00 pm CEST [4] - Abstract P1569 will cover results from the BEACON Trial, also scheduled for June 14 at 6:00 pm CEST [4] - Abstract P1059 will discuss a Phase 1b Trial of DISC-0974 in patients with Myelofibrosis and Anemia, and Abstract P1563 will present a Phase 1 study of DISC-3405 in healthy volunteers, both on June 14 at 6:00 pm CEST [5] Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases [6] - The company aims to build a portfolio of innovative therapeutic candidates targeting red blood cell biology, specifically heme biosynthesis and iron homeostasis [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39438 Disc Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 85-1612845 ...